Geoffrey Uy, MD

Bone Marrow Transplant Specialist, Medical Oncologist

Geoffrey Uy

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Geoffrey Uy, MD

Watch video on YouTube

Geoffrey Uy, MD

5 mins

Geoffrey Uy, MD medical oncologist and bone marrow transplant specialist from the Siteman Cancer Center discusses how Leukemia is a type of cancer that affects the blood or the blood forming stem cells that live in the bone marrow can affect people of any age, but is most common in kids.

Clinical Expertise

  • Acute leukemia, myelodysplastic syndromes, blood and marrow transplantation.

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 2004: American Board of Internal Medicine, Internal Medicine
  • 2007: American Board of Internal Medicine, Medical Oncology
  • 2008: American Board of Internal Medicine, Hematology

Training

  • 2001 - 2003: Resident, Internal Medicine, WashU Medicine, St. Louis, MO
  • 2003 - 2007: Fellow, Hematology and Oncology, WashU Medicine, St. Louis, MO

Education

  • 2001: MD, WashU Medicine, St. Louis, MO
  • 2001: MA, Biology and Biomedical Sciences, WashU Medicine, St. Louis, MO

Research & Selected Publications

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic…
Authors:

Crees ZD, Stockerl-Goldstein K, Ryan M, one or more additional authors omitted Uy GL

Journal & Year:

Transplant Cell Ther | 2026

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Authors:

Wieduwilt MJ, Yin J, Kour O, one or more additional authors omitted Uy GL, one or more additional authors omitted Stone RM

Journal & Year:

J Clin Oncol | 2025

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment
Authors:

Abedin S, Uy GL, Michaelis LC

Journal & Year:

Blood | 2025

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
Authors:

Levis MJ, Hamadani M, Logan BR, one or more additional authors omitted Uy GL, one or more additional authors omitted Chen YB

Journal & Year:

Blood | 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted Uy GL, DiPersio JF

Journal & Year:

Blood | 2025

Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies
Authors:

Anabtawi N, Nicolet D, Alotaibi N, one or more additional authors omitted Uy GL, one or more additional authors omitted Blachly JS

Journal & Year:

Leukemia | 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Uy GL, Walter MJ

Journal & Year:

Leukemia | 2025

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
Authors:

Uy GL, Pullarkat V, Baratam P, one or more additional authors omitted Lin TL

Journal & Year:

Blood Adv | 2024